PROPEL Contour receives CE mark. Click here to learn more.
Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Third Quarter 2021 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021 .
View HTML
Toggle Summary First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 28, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital
View HTML
Toggle Summary Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021
September 14, 2021–Alexandria, Virginia —The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2021 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 6, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021 .
View HTML
Toggle Summary Medtronic to Acquire Intersect ENT
Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio DUBLIN and MENLO PARK, Calif. , Aug. 6, 2021 /PRNewswire/ --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with
View HTML
Toggle Summary U.S. Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 26, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 23, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021 .
View HTML
Toggle Summary Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 22, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update.
View HTML
Toggle Summary Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries MENLO PARK, Calif. --(BUSINESS WIRE)--May 20, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2021 Financial Results
— Increases 2021 Revenue Guidance to $117 Million to $121 Million — MENLO PARK, Calif. --(BUSINESS WIRE)--May 10, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for
View HTML